Lumosa Therapeutics Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	16,715	32,766	42,224	11,268	6,425	6,117
Market Cap Growth	-38.50%	-22.40%	274.74%	75.37%	5.04%	17.77%
Enterprise Value	15,982	31,945	41,699	10,380	5,254	4,757
Last Close Price	99.80	194.50	250.00	68.15	39.31	40.16
PE Ratio	-	-	-	-	-	63.75
PS Ratio	532.02	914.46	1078.41	197.97	241.17	352.32
PB Ratio	11.91	21.57	21.91	7.89	3.85	2.89
P/TBV Ratio	11.99	21.71	22.09	8.05	4.01	2.95
EV/Sales Ratio	-	891.55	1065.00	182.37	197.19	273.96
Debt / Equity Ratio	0.00	0.01	0.00	0.01	0.00	0.01
Net Debt / Equity Ratio	-0.53	-0.52	-0.70	-0.58	-0.71	-0.68
Net Debt / EBITDA Ratio	2.57	2.40	3.81	2.33	4.09	3.57
Net Debt / FCF Ratio	2.24	2.19	4.53	2.43	3.90	3.18
Asset Turnover	0.02	0.02	0.02	0.03	0.01	0.01
Inventory Turnover	0.13	0.14	0.21	0.14	0.13	0.13
Quick Ratio	6.22	6.28	6.92	3.98	5.65	6.60
Current Ratio	7.37	7.37	7.64	4.76	6.44	7.23
Return on Equity (ROE)	-22.40%	-20.11%	-26.03%	-16.16%	-26.63%	5.18%
Return on Assets (ROA)	-10.25%	-11.02%	-11.78%	-13.26%	-9.03%	-13.01%
Return on Capital Employed (ROCE)	-20.90%	-22.00%	-18.50%	-26.20%	-18.30%	-20.30%
Earnings Yield	-2.13%	-1.04%	-1.01%	-2.11%	-7.70%	1.57%
FCF Yield	-1.99%	-1.10%	-0.70%	-3.04%	-4.71%	-7.40%
Buyback Yield / Dilution	-1.01%	-1.68%	-0.64%	-0.03%	-7.61%	-24.92%